AcquisitionsApr 14, 2026, 01:33 PM
Rezolve Ai slams Commerce.com's "Poison Pill" defense
AI Summary
Rezolve Ai PLC criticized Commerce.com, Inc.'s adoption of a stockholder rights plan, calling it a "Poison Pill" and an attempt by a failing Board to entrench itself. Rezolve Ai argues Commerce.com's valuation claims are misleading and that its offer presents material upside for shareholders, who have endured a 96% stock price decline. Rezolve Ai believes shareholders will have an opportunity to express their views on the Board's leadership at the May 14 election.
Key Highlights
- Commerce.com adopted a "Poison Pill" to block acquisition.
- Rezolve Ai's analyst target for Commerce.com is $11.00.
- Commerce.com's stock declined 96% from its post-IPO peak.
- Rezolve Ai's 2026 revenue guidance is $360 million.
- Rezolve Ai highlights 7.5x year-on-year growth.